go to contents

F4 Pharma GmbH

Back to list

Facts

Founded
2013
Staff
2
Organization type
RDM biotech/pharma
Region
Vienna
Cluster
LISAvienna
Focus
human health

Profile

F4 Pharma, a clinical-stage biopharmaceutical company developing F06, an anti-inflammatory therapeutic that has shown to improve vascular integrity, FX06 is a substance discovered and developed in the Medical University of Vienna and has a dual mode of action: it is reducing the capillary leak and has anti-inflammatory efficacy. In Covid-19 by reducing pulmonary vascular hyperpermeability, FX06 is supposed to lead to improved lung function and reduced time of mechanical ventilation.

R&D:Systemic capillary leak Syndrome, Acute Respiratory Distress Syndrome, Localised organ damage

Similar companies in RDM biotech/pharma

ChironWells GmbH

Organization type
RDM biotech/pharma
Region
Tyrol
Focus
human health
Details

Hermes Pharma Ges.m.b.H.

Organization type
RDM biotech/pharma
Region
Carinthia
Focus
human health
Details

Biomin Holding GmbH/DSM

Organization type
RDM biotech/pharma
Region
Lower Austria
Cluster
ecoplus
Focus
industrial processing
Details

Gilead Sciences GesmbH

Organization type
RDM biotech/pharma
Region
Vienna
Cluster
LISAvienna
Focus
human health
Details

Contact

Gersthoferstraße 103/23
1180 Wien
Vienna

Contact: Thomas Steiner (CEO)
Email: info@f4-pharma.com
Website